In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIHealth services research, ScreeningClosed35 and overOtherCDR0000640404
BUMC-H-27136, CDMRP #W81XWH-06-1-0309, 05063002, HRPO #A-13777.2, H-27136, NCT00896649

Trial Description

Summary

RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment for breast cancer. It is not yet known whether positron emission mammography is more effective than standard mammography in finding breast tumors.

PURPOSE: This phase III trial is studying positron emission mammography to see how well it works compared with standard mammography in women with dense breast tissue or who are at high risk of breast cancer.

Further Study Information

OBJECTIVES:

  • To install the breast PET system and to test and ensure its compliance with all regulatory agencies including the ACR and FDA.
  • To measure and compare the number of call-backs for positron emission mammography (PEM) imaging and conventional mammography, and to calculate the number of true positive and false positive exams for mammograms and PEM imagining using pathologic results and yearly follow-up mammogram results (cancer detection rate) in women with dense breast tissue or at high risk for breast cancer.
  • To measure and compare patient satisfaction for both conventional mammography and PEM in terms of comfort and pain.
  • To measure and compare the cost effectiveness with conventional mammography vs PEM by examining cost, examination time, and radiologist reading time.

OUTLINE: Patients undergo a conventional two-view mammogram and positron emission mammography (PEM). Immediately following treatment, patients complete a questionnaire on their satisfaction with the standard mammogram and the PEM.

After completion of study treatment, patients are followed annually.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria:
  • Dense breast tissue
  • At high-risk for breast cancer
  • No history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram

PATIENT CHARACTERISTICS:

  • Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth:
  • Hispanic
  • Haitian Creole
  • African American
  • Caucasian

PRIOR CONCURRENT THERAPY:

  • None specified

Trial Contact Information

Trial Lead Organizations/Sponsors

Boston University Cancer Research Center

Department of Defense

Gustavo MercierPrincipal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00896649
Information obtained from ClinicalTrials.gov on November 20, 2012

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top